Are you or someone you know struggling with moderate-to-severe atopic dermatitis? If so, you're likely aware of the constant discomfort and impact on daily life. But there's hope! A recent study published in Frontiers of Medicine sheds light on the real-world effectiveness and safety of Janus kinase 1 (JAK1) inhibitors in treating this condition, particularly within the Chinese population.
Researchers at Xiangya Hospital, Central South University, conducted a single-center, prospective study focusing on the use of upadacitinib and abrocitinib, two JAK1 inhibitors already approved in China for moderate-to-severe atopic dermatitis (AD). While clinical trials have shown their efficacy and safety, real-world data, especially for Asian populations, has been limited. This study aimed to fill that gap.
From June 2022 to June 2023, the researchers enrolled 90 patients with moderate-to-severe AD (as defined by an IGA score of 3-4). The participants were divided into two groups: 51 received oral abrocitinib (100 mg once daily), and 39 received oral upadacitinib (15mg once daily). They meticulously tracked demographic and clinical characteristics at the start, along with disease severity and quality of life scores (using EASI, IGA, SCORAD, and other measures) and various laboratory indicators, including total serum IgE and TEC. These assessments were performed at the beginning of the study and then again at 2, 4, 16, and 24 weeks after starting treatment.
The results are promising! Both medications demonstrated a significant reduction in disease severity and an improvement in the patients' quality of life, with noticeable effects as early as Week 2. These positive effects continued throughout the 24-week study period. By Week 4, patients in both groups showed rapid responses based on several metrics (EASI-75, EASI-90, IGA 0/1, PP-NRS4). Furthermore, serum IgE levels decreased significantly in the abrocitinib group, while TEC levels decreased in both groups. The study also found no statistically significant difference in efficacy between the two drugs after accounting for other influencing factors.
Now, let's talk about safety. During the 24-week study, 27.45% of patients treated with abrocitinib and 30.77% of those on upadacitinib reported adverse events (AEs). The most common side effect was acne, but all reported AEs were mild and resolved with symptomatic treatment. Crucially, there were no serious AEs, no treatment discontinuations due to AEs, and no deaths related to AEs.
This study provides valuable real-world evidence supporting the use of JAK1 inhibitors in treating moderate-to-severe AD in Chinese patients. However, the researchers acknowledge some limitations, such as the single-center design, the relatively small sample size, and the 24-week follow-up period.
But here's where it gets interesting... The study's findings are encouraging, but it's important to remember that this was a single-center study. Would the results be the same in a larger, multi-center study?
And this is the part most people miss... While the study highlights the benefits of these drugs, it's also crucial to consider the potential for long-term effects. The 24-week follow-up is a good start, but longer-term studies are needed to fully understand the long-term safety profile of these medications.
What do you think? Are you encouraged by these findings? Do you have any questions or concerns about JAK1 inhibitors? Share your thoughts in the comments below!
For more detailed information, the full paper is available at: https://doi.org/10.1007/s11684-024-1063-9.
